Fast Five Quiz: Prognosis of Primary Myelofibrosis

Emmanuel C. Besa, MD


July 16, 2020

The GIPSS is based exclusively on genetic markers (mutations and karyotype), whereas the MIPSS70 includes mutations and clinical risk factors.

MIPSS70+ version 2.0 is an adaptation of MIPSS70 that includes a three-tiered cytogenetic risk stratification and use of hemoglobin thresholds that are adjusted for sex and severity; this is the preferred model in the presence of cytogenetic information.

Both MIPSS70 and MIPSS70+ version 2.0 require an online score calculator, whereas GIPPS offers a lower-complexity prognostic tool that reliably identifies candidates for allo-HCT (GIPSS high-risk disease) or long-term observation with little or no therapeutic intervention (GIPSS low-risk disease).

Learn more about prognostic scoring systems for patients with PMF.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.